EuropeanRegulatory GateUpdated daily
European funding rounds in hardware and deep tech, new funds and public programmes, open calls, and the EU rules that change how founders raise capital — each with a short note on why it matters and a link to the source.
25 items
Paris-based WhiteLab Genomics raised a €23.2 million Series B led by AVP to accelerate its AI-driven genomic medicine design platform. As a biotech company building deep-tech drug-design tools, this is directly relevant to deep-tech founders raising capital in Europe.
Danish clinical-stage biopharma Breye Therapeutics closed an oversubscribed €67.5 million Series A to advance oral therapies for early retinal disease treatment, co-led by Mission BioCapital and Novo Holdings. It's a sizeable European medtech/biotech raise relevant to founders and investors tracking deep-tech healthcare funding.
Swedish biotech Omnio raised an oversubscribed €2.9 million round from existing investors to advance its plasminogen-based therapy for chronic wounds toward clinical studies. It follows a prior €4.3 million round and signals continued investor appetite for European medtech/biotech ventures at the seed stage.
Milan-based biotech Aptadir Therapeutics raised a $45 million seed round to develop treatments for difficult-to-treat genetic conditions. It is a significant biotech seed round relevant to European deep-tech and medtech founders.
UK life-sciences startup Basecamp Research raised $140m in a Series C round backed by Anthropic and Nvidia to accelerate AI-driven drug discovery. It highlights strong investor appetite for European biotech/AI hybrids, relevant for deep-tech founders seeking large growth rounds.
Items are selected and summarised automatically from public sources once a day. The summary is ours; the facts belong to the linked source — check it before acting. This is market information, not investment or legal advice.